FY2024 EPS Estimates for ZVRA Increased by Cantor Fitzgerald

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Cantor Fitzgerald raised their FY2024 earnings per share estimates for shares of Zevra Therapeutics in a note issued to investors on Wednesday, January 8th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will earn ($1.93) per share for the year, up from their previous estimate of ($1.97). Cantor Fitzgerald has a “Overweight” rating and a $25.00 price target on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.96) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.04 million. During the same quarter in the previous year, the firm earned ($0.40) EPS.

Several other equities research analysts have also recently issued reports on ZVRA. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Maxim Group boosted their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Roth Mkm lifted their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. JMP Securities initiated coverage on Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 target price for the company. Finally, Canaccord Genuity Group cut their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Zevra Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $21.57.

Zevra Therapeutics Stock Up 3.5 %

Shares of ZVRA opened at $8.53 on Friday. The firm has a fifty day moving average price of $8.78 and a 200-day moving average price of $7.58. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The firm has a market capitalization of $455.30 million, a P/E ratio of -4.33 and a beta of 2.01. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.76.

Institutional Trading of Zevra Therapeutics

Several hedge funds have recently modified their holdings of ZVRA. FMR LLC boosted its position in shares of Zevra Therapeutics by 282,687.5% in the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after purchasing an additional 2,312,384 shares in the last quarter. Geode Capital Management LLC raised its stake in Zevra Therapeutics by 14.2% in the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock valued at $7,246,000 after buying an additional 129,600 shares during the last quarter. State Street Corp boosted its holdings in Zevra Therapeutics by 7.4% in the third quarter. State Street Corp now owns 772,825 shares of the company’s stock worth $5,363,000 after acquiring an additional 52,966 shares in the last quarter. Stonepine Capital Management LLC purchased a new stake in shares of Zevra Therapeutics during the third quarter worth about $4,858,000. Finally, Vestal Point Capital LP acquired a new position in shares of Zevra Therapeutics during the third quarter valued at about $3,644,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.